Baxter's Gammagard linked to hepatitis
- The US Food and Drug Administration says that as many as 1,000 cases of hepatitis C could be linked to use of Baxter's immunoglobulin product Gammagard. The company, which faces about 50 federal lawsuits for negligence in Los Angeles and several more in state courts, received US approval to market Gammagard in 1986 without a requirement to include a virus-killing step in the drug's manufacturing process. Baxter now sells a virally-inactivated version of the drug called Gammagard S/D, and says it did not impose the virus-killing step earlier because its experience indicated that other immunoglobulin products already on the market (untreated) did not transmit the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze